$TGTX News

B of A Securities Maintains Underperform on TG Therapeutics, Raises Price Target to $20

HC Wainwright & Co. Reiterates Buy on TG Therapeutics, Maintains $70 Price Target

TG Therapeutics Starts Phase 2 Clinical Study Of BRIUMVI In Adult Participants With Treatment-Resistant Schizophrenia

TG THERAPEUTICS INC (NASDAQ:TGTX): High-Growth Momentum Meets Minervini Trend Template Technical Strength

TG Therapeutics Stock Rises Thursday: What's Driving The Gains?

TG Therapeutics Stock Is Surging Today: What's Driving The Action?

TG Therapeutics, Inc. (TGTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Why Is TG Therapeutics Stock Gaining Tuesday?

TG Therapeutics Initiates Phase 2 Clinical Trial Evaluating BRIUMVI As Maintenance Therapy Following Induction With Efgartigimod In Adult Patients With MG

TG Therapeutics Announces Topline Phase 1 Data For BRIUMVI In Patients With Myasthenia Gravis

TG Therapeutics Stock Surges After Drug Trial Update

TG Therapeutics Announces Pharmacokinetic, Pharmacodynamic, Safety, And Tolerability Data From Phase 1 Clinical Trial Evaluating Subcutaneous Formulation Of Ublituximab As Compared To IV BRIUMVI

TG Therapeutics Publishes Post-Hoc Pooled Analysis Of Its Phase 3 ULTIMATE I, II Trials Of BRIUMVI To Treat Relapsing Forms Of Multiple Sclerosis

TG Therapeutics: 'Strong Buy' Amid BRIUMVI Expansion Win And Boosted 2026 Outlook

HC Wainwright & Co. Reiterates Buy on TG Therapeutics, Maintains $70 Price Target

TG Therapeutics Announces Positive Topline Results from Phase 3 ENHANCE Trial

TG Therapeutics Says Topline Results From Phase 3 ENHANCE Trial Meets Primary Endpoint, Demonstrating Bioequivalent Drug Exposure Between Currently Approved BRIUMVI Day 1 And Day 15 Initiation Dosing And New Single Infusion On Day 1 Only

TG Therapeutics Announces Data Presentations for BRIUMVI® at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting

TG Therapeutics To Highlight BRIUMVI Data In Adults With Relapsing Forms Of Multiple Sclerosis At 2026 CMSC Annual Meeting

Multiple Sclerosis-Focused Biotech Quadruples Its Profit, Raises Sales Forecast